IKZF1表达是新诊断标危多发性骨髓瘤接受来那度胺联合强化化疗的预后标志物:德国骨髓瘤研究组(DSMM)研究
该研究分析60例新诊断多发性骨髓瘤患者预处理浆细胞中IKZF1、IKZF3、CRBN和BSG的mRNA表达水平与预后的关系,患者均在接受来那度胺联合强化化疗的临床试验中治疗。IKZF1表达最低四分位组(Q1)较其余四分位组(Q2-Q4)的3年无进展生存率更高(86% vs 51%,P=0.01),总生存率亦更高(100% vs 74%,P=0.03)。亚组分析显示IKZF1、IKZF3和BSG表达对细胞遗传学标危患者无进展生存有显著影响,高危患者中未见显著影响。
要点
- IKZF1表达最低四分位组3年PFS为86%,其余组为51%(P=0.01)。
- IKZF1表达最低四分位组总生存为100%,其余组为74%(P=0.03)。
- IKZF1、IKZF3和BSG表达对PFS的影响仅在细胞遗传学标危患者中显著,高危患者中不显著。
核心结论
- 数据提示IKZF1、IKZF3和BSG表达水平在接受来那度胺治疗的多发性骨髓瘤中具有预后作用。
研究设计与样本
- 研究分析了60例新诊断多发性骨髓瘤患者预处理浆细胞中IKZF1、IKZF3、CRBN和BSG的mRNA表达水平,患者均在接受来那度胺联合强化化疗的临床试验中治疗。
主要发现
- IKZF1表达最低四分位组(Q1)的3年无进展生存率为86%,其余四分位组(Q2-Q4)为51%(P=0.01)。
- IKZF1表达最低四分位组(Q1)的总生存率为100%,其余四分位组(Q2-Q4)为74%(P=0.03)。
- 亚组分析显示IKZF1、IKZF3和BSG表达水平对细胞遗传学标危患者的无进展生存有显著影响,对高危患者无显著影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lenalidomide is an immunomodulatory compound with high clinical activity in multiple myeloma. Lenalidomide binding to the Cereblon (CRBN) E3 ubiquitin ligase results in targeted ubiquitination and degradation of the lymphoid transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) leading to growth inhibition of multiple myeloma cells. Recently, Basigin (BSG) was identified as another protein regulated by CRBN that is involved in the activity of lenalidomide. Here, we analyzed the prognostic value of IKZF1, IKZF3, CRBN and BSG mRNA expression levels in pretreatment plasma cells from 60 patients with newly diagnosed multiple myeloma uniformly treated with lenalidomide in combination with intensive chemotherapy within a clinical trial. We found that IKZF1 mRNA expression levels are significantly associated with progression-free survival (PFS). Patients in the lowest quartile (Q1) of IKZF1 expression had a superior PFS compared with patients in the remaining quartiles (Q2-Q4; 3-year PFS of 86 vs 51%, P=0.01). This translated into a significant better overall survival (100 vs 74%, P=0.03). Subgroup analysis revealed a significant impact of IKZF1, IKZF3 and BSG expression levels on PFS in cytogenetically defined standard-risk but not high-risk patients. Our data suggest a prognostic role of IKZF1, IKZF3 and BSG expression levels in lenalidomide-treated multiple myeloma.
引用
- Krönke J, Kuchenbauer F, Kull M, et al. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). Leukemia. 2016. PMID: 28017969. doi:10.1038/leu.2016.384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。